Healthcare / Diagnostics & ResearchShanghai
$49.83
-0.96 (-1.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $13.9M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.0B
P/E
142.4x
↑EV/EBITDA
68.6x
↑ROE
1.1%
↑Gross Margin
78.0%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-18.9%
FCF CAGR
—
FCF margin
9.5%
FCF / Net income
1.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $161.9M · net income $10.1M · FCF $15.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $161.9M | $161.9M | $177.4M | $164.4M | $303.8M |
| Net Income | $10.1M | $10.1M | $-7.8M | $8.3M | $23.3M |
| EBITDA | $26.8M | $26.8M | $2.2M | $21.0M | $41.7M |
| EPS | 0.26 | 0.26 | -0.20 | 0.21 | 0.61 |
| Gross Margin | 78.0% | 78.0% | 79.5% | 81.3% | 65.5% |
| Operating Margin | -8.8% | -8.8% | -6.8% | -5.1% | 6.2% |
| Net Margin | 6.2% | 6.2% | -4.4% | 5.0% | 7.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 |
| Current Ratio | 14.97 | 14.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.3M | $15.3M | $13.9M | $-3.2M | $-25.3M |
| Returns | |||||
| ROE | 1.1% | 1.1% | -0.9% | 0.9% | 2.4% |
| Valuation | |||||
| P/E | 142.37 | 142.37 | — | 216.95 | 77.84 |
| EV/EBITDA | 68.62 | 68.62 | 492.66 | 46.01 | 36.63 |
| P/B | 2.12 | 2.12 | 1.46 | 1.63 | 1.89 |
| Growth & Yield | |||||
| Revenue Growth | -8.7% | -8.7% | 7.9% | -45.9% | — |
| EPS Growth | 230.0% | 230.0% | -195.2% | -65.6% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
157.2%
EPS terminal req.
$4.42
Spread vs growth
72.8%
5Y implied EPS CAGR
83.1%
EPS terminal req.
$5.35
Spread vs growth
146.9%
10Y implied EPS CAGR
41.9%
EPS terminal req.
$8.62
Spread vs growth
188.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.20 → 0.26
Residual
+25.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.